R. Kalyani

发表

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.

T. Ciuleanu, M. Rodríguez-Torres, I. Bondarenko, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Analogs of Lactam Derivatives of α-Melanotropin with Basic and Acidic Residues

M. Bednarek, R. Tang, T. Macneil, 2000 .

Structure–activity relationship of linear tetrapeptides Tic-DPhe-Arg-Trp-NH2 at the human melanocortin-4 receptor and effects on feeding behaviors in rat

D. Macintyre, A. Patchett, R. Nargund, 2005, Peptides.

Analogs of MTII, lactam derivatives of alpha-melanotropin, modified at the N-terminus, and their selectivity at human melanocortin receptors 3, 4, and 5.

M. Bednarek, L. V. D. van der Ploeg, T. Macneil, 1999, Biochemical and biophysical research communications.

Melanocortin subtype 4 receptor agonists: structure-activity relationships about the 4-alkyl piperidine core.

L. V. D. van der Ploeg, A. Patchett, R. Nargund, 2007, Bioorganic & medicinal chemistry letters.

Design and syntheses of melanocortin subtype-4 receptor agonists: evolution of the pyridazinone archetype.

F. Ujjainwalla, L. V. D. van der Ploeg, C. Rosenblum, 2003, Bioorganic & medicinal chemistry letters.

ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors.

M. Tota, L. V. D. van der Ploeg, T. Macneil, 1997, Biochemical and biophysical research communications.

Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus

E. Morand, J. Merrill, E. Vital, 2021, Lupus.

Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of Staphylococcus aureus and Pseudomonas aeruginosa pneumonia in the ICU

H. Goossens, M. Bonten, M. Wolkewitz, 2017, BMC Infectious Diseases.

Structure-function studies on the cyclic peptide MT-II, lactam derivative of α-melanotropin☆ ☆ Throughout this report, the numbering of the amino acid residues in α-MSH has been retained for all linear and cyclic peptides.

M. Bednarek, B. Arison, T. Macneil, 1999, Peptides.

Structure-function studies on the cyclic peptide MT-II, lactam derivative of alpha-melanotropin.

M. Bednarek, M. V. Silva, B. Arison, 1999, Peptides.

Analogs of lactam derivatives of alpha-melanotropin with basic and acidic residues.

M. Bednarek, L. V. D. van der Ploeg, T. Macneil, 2000, Biochemical and biophysical research communications.

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

E. Morand, R. Furie, R. Kalyani, 2021, Lupus Science & Medicine.

Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: discovery of the dihydropyridazinone motif.

F. Ujjainwalla, L. V. D. van der Ploeg, R. Tang, 2005, Bioorganic & medicinal chemistry letters.

Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.

L. V. D. van der Ploeg, A. Patchett, R. Nargund, 2006, Bioorganic & medicinal chemistry letters.

Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist.

J. Metzger, D. Macintyre, L. V. D. van der Ploeg, 2005, Bioorganic & Medicinal Chemistry Letters.

Optimization of privileged structures for selective and potent melanocortin subtype-4 receptor ligands.

J. Metzger, L. V. D. van der Ploeg, C. Rosenblum, 2010, Bioorganic & medicinal chemistry letters.

1-Amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid as a Tic mimetic: application in the synthesis of potent human melanocortin-4 receptor selective agonists.

L. V. D. van der Ploeg, A. Patchett, R. Nargund, 2005, Bioorganic & medicinal chemistry letters.

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

I. Bruce, K. Kalunian, E. Morand, 2022, Annals of the Rheumatic Diseases.

A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.

S. Block, Yuan Yuan, F. Dubovsky, 2019, Vaccine.

Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist.

D. Johnston, D. Macintyre, L. V. D. van der Ploeg, 2002, Journal of medicinal chemistry.

OP0049 EFFICACY OF ANIFROLUMAB IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT SUBGROUP ANALYSIS OF BICLA RESPONSE IN 2 PHASE 3 TRIALS

E. Morand, R. Furie, R. Kalyani, 2020, Annals of the Rheumatic Diseases.

Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist.

J. Metzger, D. Macintyre, L. V. D. van der Ploeg, 2005, Bioorganic & medicinal chemistry letters.

Selective, high affinity peptide antagonists of alpha-melanotropin action at human melanocortin receptor 4: their synthesis and biological evaluation in vitro.

M. Bednarek, L. V. D. van der Ploeg, M A Bednarek, 2001, Journal of medicinal chemistry.

Final analysis: Randomized, blinded, placebo-controlled phase II trial of sorafenib with and without mapatumumab in patients with advanced hepatocellular carcinoma (HCC).

T. Ciuleanu, G. Aktan, I. Bondarenko, 2014 .

Plasma protein biomarkers reflective of the host response in patients developing Intensive Care Unit-acquired pneumonia

T. van der Poll, M. Bonten, M. Wolkewitz, 2023, Critical Care.